Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 25, 2025 11:58 ET | Source: Enlivex Therapeutics Ltd

Enlivex 宣布完成 2.12 亿美元私募融资，拟通过积累 RAIN 代币开启全球首个预测市场数字资产储备战略，并任命意大利前总理 Matteo Renzi 出任董事会成员

- 私募融资完成后，Enlivex 将通过积累 RAIN 代币，采用全球首个基于 RAIN 预测市场代币的数字资产储备战略。 - RAIN 是一个完全去中心化的预测与期权协议，重新定义了预测市场生态系统，并为链上市场的创建提供强大支撑——平台以透明度、自动化和社区参与为核心理念而构建。 - 意大利前总理 Matteo Renzi 先生将在私募融资完成后获任 Enlivex 董事会成员。 -...
November 25, 2025 11:58 ET | Source: Enlivex Therapeutics Ltd

エンライベックス (Enlivex)、RAINトークンの蓄積を通じた世界初の予測市場デジタル資産財務戦略を開始するための2億1,200万ドル (約333億円) の私募および、イタリア元首相マッテオ・レンツィ (Matteo Renzi) の取締役任命を発表

- 私募のクロージング後、エンライベックスはRAINトークンの蓄積を通じて、世界初のRAIN予測市場トークンデジタル資産財務戦略を採用する。 - RAINは完全に分散化された予測・オプションプロトコルで、予測市場エコシステムを再定義し、透明性、自動化、コミュニティ参加を基盤としたオンチェーン市場創出のための強力なプラットフォームを提供する。 -...
November 25, 2025 11:58 ET | Source: Enlivex Therapeutics Ltd

Enlivex mengumumkan Penempatan Persendirian bernilai AS$212,000,000 untuk Memulakan Strategi Perbendaharaan Aset Digital Pasaran Ramalan Pertama di Dunia, melalui Pengumpulan token RAIN, serta Pelantikan Matteo Renzi, Bekas Perdana Menteri Itali, ke dalam Lembaga Pengarahnya

- Selepas penutupan penempatan persendirian, Enlivex akan mengguna pakai strategi perbendaharaan aset digital token pasaran ramalan RAIN pertama di dunia melalui pengumpulan token RAIN. - RAIN ialah...
November 24, 2025 07:55 ET | Source: Enlivex Therapeutics Ltd

Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

- Upon the closing of the private placement, Enlivex will adopt the world’s first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation. - RAIN is a fully...
November 24, 2025 06:40 ET | Source: Enlivex Therapeutics Ltd

Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis

Nes-Ziona, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ( Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...
October 28, 2025 08:15 ET | Source: Enlivex Therapeutics Ltd

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

Ness-Ziona, Israel, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
September 29, 2025 08:15 ET | Source: Enlivex Therapeutics Ltd

D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

Nes-Ziona, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, will participate in a...
September 11, 2025 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results

Allocetra™ demonstrated statistically significant and clinically meaningful improvements in pain and function in Phase IIa trial in primary osteoarthritis patients Six-month data expected...
September 09, 2025 08:00 ET | Source: Enlivex Therapeutics Ltd

Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Nes-Ziona, Israel, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the...
August 18, 2025 07:45 ET | Source: Enlivex Therapeutics Ltd

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

ENX-CL-05-001 Trial: 3-months topline data - In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee...